We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Allergan plc | NYSE:AGN | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 193.02 | 0 | 01:00:00 |
Hedge fund manager Bill Ackman said Wednesday the poison-pill defense put in place by Allergan Inc. in the wake of a bid by larger rival Valeant Pharmaceuticals International doesn't necessarily complicate the bidding process.
"It depends on why the poison pill was put in place. If the poison pill is an entrenchment device then that's a bad thing," he said in comments on CNBC.
"If the poison pill is a way for the board to explore other alternatives and have a reasonable period of time to do that, then that's fine," he said. "I think a pill that is put in place for ninety days, that gives a board a way to look at other alternatives" is reasonable.
Valeant chief executive Michael Peason, in the same interview, said he was "disappointed" by the poison pill but was confident that the deal would still get done, adding the due diligence and nearly 10% share held by Ackman's Pershing Square makes the deal much more likely.
Both Mr. Pearson and Mr. Ackman repeated they saw their moves as a way to create shareholder value over the long term, and Mr. Ackman noted his partnership with Valeant stipulates that "we hold" the Allegan stock.
Mr. Ackman said there was no violation of insider trading rules in the proposal. "We formed a partnership and the partnership has various terms, giving us the right and the permission to go buy a stake in Allergan," he said.
"They shared with us their interest in Allergan, their interest in possibly taking over the company on the basis that we work with them to assist them in doing so, and part of that involved our buying a stake in Allergan,' he said.
Full story at www.cnbc.com
Write to nymonitoring@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Allergan Chart |
1 Month Allergan Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions